Gastric Cancer Clinical Trials

Gastric Cancer Clinical Trials

Gastric , GEJ and Esophageal cancer studies recruiting patients need your help. Receive premium care & cutting edge treatments by enrolling in clinical trials today.

Gastric Cancer Clinical Trials

Here are the 6 most popular medical studies for

Washington, District of Columbia

Procedure

Endoscopic spray cryotherapy for Barrett's Esophagus

Recruiting3 awardsPhase 4
Washington, District of Columbia

In this prospective single center study, up to 25 patients with Barrett's esophagus with LGD or no dysplasia (Group 1), 25 patients with HGD/IMCA (Group 2), 25 patients with esophageal carcinoma confined to the esophageal wall (Group 3) and 25 patients with severe esophageal squamous dysplasia (Group 4) will be treated with endoscopic cryotherapy. This study is single arm and no blinding will be utilized. Interim analysis of the data will be reviewed with a DCI statistician after 14 patients in each group have been treated with cryotherapy and if safety and efficacy is documented to that point in time, we will request the ability to extend the enrollment to a maximum allowable amount of 25 patients per group. The proposed study duration is seven years, allowing two years for patient enrollment and 5 years for post treatment follow-up. Study duration per patient will total approximately six years. Patients with Barrett's esophagus with no dysplasia or low grade dysplasia (group 1) will be treated with cryotherapy at six week intervals until Barrett's mucosa is ablated or six treatments are administered. Patients with Barrett's HGD and IMCA or severe esophageal squamous dysplasia (groups 2 and 4) will be treated with cryotherapy at six-week intervals until Barrett's mucosa is ablated or six treatments are administered. More advanced mass lesions are typically more difficult to eradicate with ablative therapies and may progress faster than patients with IMCA, therefore, patients with more advanced cancer (group 3) will be treated every 2 weeks until the lesion is eradicated up to eight treatments. After cryotherapy treatment is complete (i.e. the esophagus has re-epithelialized with normal squamous epithelium for Groups 1, 2, 4 and the tumor is locally controlled/absent in Group 3), patients will be assessed by endoscopy and biopsy every three months for one year, every six months for two years, then annually for two years (flow sheet - appendix 1; study schedule - appendix 2).
Los Angeles, California

Alkylating agents

Oxaliplatin +1 More for Stomach Cancer

Recruiting3 awardsPhase 2
Los Angeles, California

This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after patients take the drugs capecitabine, oxaliplatin and cetuximab. Capecitabine (also called Xeloda) is a drug that has been approved by the Food and Drug Administration (FDA). Capecitabine has been approved for treatment of cancer of the colon and rectum. Oxaliplatin is another drug approved by the FDA. Oxaliplatin is also approved for treatment of cancer of the colon and rectum. Cetuximab is also a drug approved by the FDA for the treatment of cancer of the colon and rectum, as well as cancer of the head and neck. Capecitabine, oxaliplatin and cetuximab are not approved for gastric or gastroesophageal cancer. They are considered experimental drugs for this study. The purpose of this study is to see how long it takes patients' tumors to progress when they are taking oxaliplatin and capecitabine. Another purpose is to see how many tumors respond to this drug combination. The investigators also want to see how long people live when taking these drugs. The side effects of this drug combination will also be evaluated. This study will also measure the levels of certain genes (the cell's blueprint) in tumors. These genes affect how peoples' bodies react to the cancer drugs. Genes will also be measured in the blood. The investigators want to see how these genes can predict response to these study drugs.

Popular filter options for trials

Adenocarcinoma Clinical Trials

View 67 Adenocarcinoma medical studies.

Gastric Adenocarcinoma Clinical Trials

View 53 Gastric Adenocarcinoma medical studies.

HER2 Positive Clinical Trials

View 15 HER2 positive medical studies.

Phase 3 Gastric Cancer Clinical Trials

View 94 phase 3 gastric cancer medical studies.

Gastric Cancer Clinical Trials With No Placebo

View 94 gastric cancer medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to

What are the top hospitals conducting undefined research?

In the quest to conquer various medical conditions, clinical trials play a crucial role in driving innovation and improving patient outcomes. When it comes to pioneering research in an undefined area, several esteemed hospitals across the United States are at the forefront of these efforts. One such institution is M D Anderson Cancer Center located in Houston, where 12 active trials focused on this unidentified condition are currently underway. Not far behind is the Washington University School of Medicine in Saint Louis with eight ongoing undefined trials. These institutions are dedicated to unraveling the mysteries surrounding this enigmatic condition.

Meanwhile, Massachusetts General Hospital in Boston also contributes significantly by conducting six active clinical trials related to this unknown ailment. This hospital has earned its reputation as a leading center for medical advancements and continues its commitment to exploring new frontiers through innovative research protocols.

The Memorial Sloan Kettering Cancer Center in New york stands shoulder-to-shoulder with these institutions, prioritizing investigations into this undefined condition with six active clinical trials taking place within their premises. With their wealth of expertise and resources, they strive to shed light on critical aspects that remain unexplored.

Lastly, we have Moffitt Cancer Center situated in Tampa making notable strides by conducting five ongoing clinical trials aimed at unravelling information about this mysterious condition.

While we await further clarity and understanding regarding this yet-unidentified illness or disorder being studied at these top hospitals offering unprecedented opportunities for advancement; we can appreciate the tireless dedication of researchers working towards breakthroughs that will undoubtedly enhance our knowledge base and ultimately bring us closer to solutions needed for improved healthcare outcomes worldwide

Which are the best cities for undefined clinical trials?

When it comes to undefined clinical trials, several cities stand out as leading hubs for research and innovation. Houston, Texas boasts 29 active trials exploring treatments like Arm A: FLOT-TNT (Investigational Arm), Nivolumab, and Phase 1 elzovantinib. Boston, Massachusetts follows closely behind with 25 ongoing studies focused on Phase 1 elzovantinib, Trastuzumab deruxtecan, and Nivolumab interventions. Los Angeles, California is also a significant player with 22 active trials examining treatments such as Telatinib, DKN-01 300mg, and Cardiac Aggressive Risk MitigAtion Plan. These cities offer individuals access to cutting-edge clinical trials that pave the way for advancements in medical care and potential breakthroughs in treatment options.

Which are the top treatments for undefined being explored in clinical trials?

In the field of undefined treatment research, clinical trials are uncovering promising options. Leading the pack is daratumumab, a drug currently being tested in six active trials. Since its introduction in 2012, it has been involved in 134 breast cancer trials. Belantamab mafodotin follows with four ongoing trials and a total of 26 breast cancer studies since its debut in 2018. Another notable contender is lenalidomide, which has three active clinical trials for breast cancer and an impressive track record of 280 all-time studies since its first listing in 2003. These treatments hold great potential as researchers strive to find effective solutions for patients facing undefined conditions.

What are the most recent clinical trials for undefined?

In the realm of clinical trials, several recent studies have emerged in search of effective treatments for undefined conditions. These trials include the evaluation of Olympus GIF 190 endoscope, a phase 2 study that aims to enhance diagnostic capabilities and improve patient outcomes. Additionally, CA-4948 is undergoing a phase 1 trial to assess its potential as a therapeutic option for this enigmatic condition. Another promising avenue being explored involves treatment approaches such as gastrectomy with HIPEC (hyperthermic intraperitoneal chemotherapy) in a phase 2 trial. Furthermore, the combination therapy of tadalafil and chemotherapy is being investigated in another phase 2 study, showing promise for patients with undefined conditions. Lastly, Enterotracker is currently in a phase 1 trial, offering hope for improved diagnostics and understanding within this challenging field.

What undefined clinical trials were recently completed?

Recently completed clinical trials that were not specified include a range of diverse studies across various medical fields. These trials, while unspecified in detail, represent the tireless efforts of researchers and participants to advance medical knowledge and improve patient care. Though specific information is lacking, these completed trials contribute to the collective body of evidence and pave the way for future discoveries and breakthroughs.